Invivyd (IVVD) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and milestones

• Focuses on antibody-based prevention and treatment of COVID-19, with a technology platform enabling serial innovation in SARS-CoV-2 medicines.

• Launched PEMGARDA, an authorized antibody, showing 84%-85% reduction in symptomatic COVID-19 in a registrational study.

• Committed to broadening access and ongoing innovation to address the persistent medical burden of COVID-19.

• Next-generation molecules are in development, aiming for improved potency and more patient-friendly administration.

Scientific and clinical insights

• PEMGARDA targets a stable, immunorecessive region of the spike protein, providing resilience against viral evolution.

• Phase III data showed no hospitalizations in the treated cohort, highlighting strong efficacy.

• Placebo-controlled cohort included a high-risk, comorbid, and aged population, not just healthy individuals.

• Efficacy observed even at lower drug exposures, suggesting potential for dose optimization.

Commercial strategy and market opportunity

• 2024 revenue guidance for PEMGARDA is $150-$200 million, requiring about 30,000 infusions.

• Addressable population includes 8-9 million immunocompromised Americans, with potential for broader reach.

• Annual net revenue per patient is about $18,000, with plans to lower price and expand access over time.

• Commercial team expanded in June, shifting from passive to active biopharma commercialization, focusing on access and demand generation.